MAZE

Maze Therapeutics Inc

Jul 29 • 04:00PM ET

15.74

Dollar change -0.62
Percentage change -3.79	%

Healthcare • Biotechnology • USA • NASD

Held by: IWM VTI VXF IWN SCHA VTWO SBIO IWC BBC IWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	70.13%	Shs Outstand	43.80M	Perf Week	-7.08%
Market Cap	689.37M	Forward P/E	-	EPS next Y	-3.40	Insider Trans	0.00%	Shs Float	13.08M	Perf Month	29.76%
Enterprise Value	420.82M	PEG	-	EPS next Q	-0.84	Inst Own	39.18%	Short Float	14.84%	Perf Quarter	87.83%
Income	-	P/S	-	EPS this Y	-396.53%	Inst Trans	17.82%	Short Ratio	15.00	Perf Half Y	-
Sales	-	P/B	2.36	EPS next Y	8.18%	ROA	-	Short Interest	1.94M	Perf YTD	-1.32%
Book/sh	6.67	P/C	2.34	EPS next 5Y	-	ROE	-	52W High	19.19 -17.98%	Perf Year	-
Cash/sh	6.72	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	6.71 134.58%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.06% 10.68%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.49	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	16.10	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.52	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	16.10	EPS Q/Q	-23.31%	SMA20	2.40%	Beta	-	Target Price	25.20
Payout	-	Debt/Eq	0.09	Sales Q/Q	-	SMA50	18.99%	Rel Volume	0.89	Prev Close	16.36
Employees	125	LT Debt/Eq	0.07	Earnings	May 14 AMC	SMA200	33.89%	Avg Volume	129.35K	Price	15.74
IPO	Jan 31, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-59.02% -	Trades		Volume	117,840	Change	-3.79%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-25	Initiated	H.C. Wainwright	Buy	$34
Jul-08-25	Initiated	Wedbush	Outperform	$17

Jul-10-25 04:05PM	Maze Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-29-25 07:30AM	Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference (GlobeNewswire) +6.01%
May-14-25 04:01PM	Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones (GlobeNewswire) -8.11%
May-13-25 07:30AM	Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
Mar-31-25 07:30AM	Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights (GlobeNewswire)
05:02PM	Loading…
Mar-26-25 05:02PM	Maze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist (SeekingAlpha) -7.48%
Feb-25-25 04:11PM	Maze Therapeutics receives positive ratings following recent IPO (Investing.com) +10.69%
Feb-10-25 07:09AM	Maze Therapeutics doses first subject in Phase II AKD treatment trial (Clinical Trials Arena)
Feb-07-25 08:00AM	Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease (GlobeNewswire)
Jan-30-25 08:13PM	Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg)
07:30PM	Maze Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
02:57PM	Metsera, Maze secure combined $415 million in IPOs (BioPharma Dive)

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes Compass platform, which allows to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 28, 2019 and is headquartered in San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MAZE

Maze Therapeutics Inc

Upgrade your FINVIZ experience